Freedom from documented symptomatic atrial fibrillation/atrial tachycardia/atrial flutter (hereinafter collectively referred to as "atrial tachyarrhythmias") based on electrocardiographic data during the effectiveness evaluation period (Day 91-361). Acute procedure failures, antiarrhythmic drug(AAD) changes and repeat ablation occurring during evaluation period were deemed as primary effectiveness failures

137 Study-eligible subjects with per-protocol procedure. CENSORED: 1 lost to follow-up subject without recurrence

Peri-procedural serious adverse events (SAEs) are those non-primary SAEs occurred within 8-30 days post procedure

Safety cohort, including Enrolled subjects who underwent insertion of the study catheter.

Primary safety endpoint consists of primary adverse events (AE) within 7 days post procedure Or pulmonary vein stenosis and atrio-esophageal fistula events that occurred within 12 months post-procedure. Primary adverse events include death, myocardial infarction, pulmonary vein stenosis, diaphragmatic paralysis, atrio-esophageal fistula, transient ischemic attack, stroke / cerebrovascular accident, thromboembolism, pericarditis, cardiac tamponade, pericardial effusion, pneumothorax, atrial perforation, vascular access complications, pulmonary edema, initial and prolonged hospitalization (excluding those due to pre-existing arrhythmia recurrence), heart block.

144 subjects that had study catheter inserted into their body; INCLUDES study ineligible & untreated subjects

Acute effectivenesss is defined as confirmation of entrance block into all Pulmonary veins

Effectiveness cohort, defined as those enrolled subjects who underwent insertion of the study catheter and an AF ablation procedure. Subjects without RF energy delivery will be excluded (i.e. discontinued subjects).

Late onset serious adverse events (SAEs) are those non-primary SAEs occurred after 31 days post procedure

Safety cohort, including Enrolled subjects who underwent insertion of the study catheter.